Agilent reported Q1 FY2026 revenue of USD 1.80 billion, up 7.0%, with GAAP net income of USD 305 million and GAAP diluted EPS of USD 1.07. Non-GAAP net income was USD 386 million and non-GAAP EPS was USD 1.36. By segment in Q1 FY2026, Life Sciences and Diagnostics Markets Group revenue was USD 679 million with a 16.0% operating margin; Agilent CrossLab Group revenue was USD 758 million with a 31.6% operating margin; and Applied Markets Group revenue was USD 361 million with a 25.8% operating margin. Management cited continued momentum in its instrument-replacement cycle, strong engagement in Enterprise Services, and portfolio innovation, while noting it navigated the impact of a major U.S. snowstorm late in the quarter. For FY2026, Agilent forecast revenue of USD 7.3 billion to USD 7.5 billion and non-GAAP EPS of USD 5.90 to USD 6.04. For Q2 FY2026, it guided revenue of USD 1.79 billion to USD 1.82 billion and non-GAAP EPS of USD 1.39 to USD 1.42.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225435556) on February 25, 2026, and is solely responsible for the information contained therein.